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WHY IS THE EFFECTIVENESS OF BREAST 
CANCER SCREENING STILL DISCUSSED? 
Curative therapy for breast cancer detected at an 
advanced stage is insufficient. Breast cancer screening is 
designed to detect tumours at such an early stage that they 
can still be treated effectively. The chance of dying of breast 
cancer is thus reduced for those women who participate in 
high quality screening. Various trial projects, in which 
women were invited to participate in mammographic 
screening, have shown that a reduction in breast cancer 
mortality is, indeed, achieved. In 1963 the randomised 
Health Insurance Plan (HIP) trial was set up in New York 
[l]. More than 60 000 women aged 40-65 years who were 
insured under the Health Insurance Plan of Greater New 
York were randomly divided into two groups. Half the 
women were invited for mammographic screening and clini- 
cal examination (the study population). The other half were 
not, acting as the control population. Women in the study 
group were offered screening a total of four times, at yearly 
intervals. After 10 years, the mortality from breast cancer of 
patients (diagnosed within 5 years after entry) aged 50 years 
and over was 32% lower in the study population than in the 
control population. 
Swedish trials with new technology (film-screen mammo- 
graphy and media-lateral oblique views) were set up towards 
the end of the 1970s. The Kopparberg/&tergBtland trial 
covered two rural areas in the south-east and mid-west of 
Sweden [2]. Randomisation was carried out by dividing 
each of nineteen homogenous social-economic areas into 
(one or more) areas with a control group and a study 
group. After an average follow-up period of 6 years for each 
woman offered screening, the first results were published 
showing a significant reduction in mortality from breast 
cancer of 39% in the study population for women aged 50- 
74 years. Randomised screening trials were also started in a 
number of Swedish urban areas: MalmB, Stockholm and 
Goteborg. In two areas in the United Kingdom, women 
were invited for mammographic screening; women were 
encouraged to carry out breast self-examination in a further 
two areas, and there were four control areas. Some element 
of randomisation was added at the beginning of Edinburgh, 
one of the two areas where mammographic screening was 
carried out: 84 general practices were randomly distributed 
into practices where women were invited and those where 
they were not. 
To date, all these randomised trials, and also non- 
randomised projects in the United Kingdom, The 
Netherlands and Italy, and a project in Canada which 
randomised volunteers, have proven to reduce breast 
cancer mortality for women invited aged 50-69 years. 
They, therefore, confirm the theoretical concept of 
screening and some of the clinical evidence. Clinical studies 
had shown that, for breast cancer, the size of the primary 
tumour at initial treatment and, therefore, the time of detec- 
tion correlates strongly with the probability of metastatic 
dissemination. The greater the clinical volume, the higher 
the proportion of metastases appearing later during the 
course of disease following primary treatment [3]. In a more 
recent study on 103 primary breast cancers, it was found 
that significantly higher degrees of vascularisation (by count- 
ing of microvessels) were found in tumours than in normal 
tissue and this was significantly associated with node metas- 
tases [4]. The results suggested that angiogenesis is closely 
linked to metastasis, that metastasis is only acquired at a 
critical density of vessels, and that this process occurs as 
tumours enlarge (or become poorly differentiated). The 
detection and treatment of cancers before a critical number 
of blood vessels has been induced could then, theoretically, 
lead to a reduction in cancer mortality. 
BREAST CANCER MORTALITY REDUCTION: NO 
DIMINISHING RETURN WITH TIME 
Since the publication of the first European results in 1985 
showing a 39% mortality reduction [2], no other trial has 
ever published such a large difference in effect. The first 
results from Malmij were published in 1988 [5], showing a 
seemingly more unfavourable 21% reduction in women 
aged 55 and over after an average study period of more 
than 8 years. This then, has consistently led to discussions 
on the ‘real’ efficacy of mammographic screening. It is 
suggested that the high quality in the earlier trials is either 
not sustained in the more modern situations or that changes 
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outside of the screening programme influence the effect of 
screening between the invited (for screening) group and the 
control group as time goes by. 
Although both explanations should not be ruled out, im- 
portant characteristics of the screening policies in the two 
aforementioned Swedish trials, and all trials in general, such 
as screening interval, attendance rate, follow-up period and 
age groups, should first be considered, since these markedly 
differ. 
A combined analysis of all five randomised Swedish trials 
with more than 250 000 women and 10 years of follow-up 
has confirmed the earlier publications: at the end of 
December 1989, a 29.5% statistically significant difference 
in breast cancer mortality was found for women aged 50-69 
years invited for screening [6]. Weighted for trial sizes, the 
Kopparberg, ostergotland and Malmo trials had earlier 
shown a 32% average reduction [7]. So, are the critics 
right? [8]. Is there a diminishing return with time in breast 
cancer mortality reduction due to screening? 
The newest results include the Stockholm and Goteborg 
trials with substantially shorter follow-up, less broad age 
ranges, intermediate attendance rates, and other screening 
intervals than the earlier started and reported three Swedish 
trials. Computer modelling using one underlying model that 
incorporates both the natural history of breast cancer and 
the performance of mammographic screening for all five 
trials, but taking into account as many relevant differences 
in screening policy between the trials, have made it plausible 
that the more recently observed results are indeed more 
favourable with regard to the effect of screening than esti- 
mated earlier [9]. If the earlier experience in the effect of 
screening (the improvement in prognosis for early screen- 
detected cancers) from the three Malmo, Kopparberg, 
Gstergotland trials had been the reference value for all five 
Swedish trials, one would even have expected a smaller 
overall reduction of 26.5% compared to the 29.5% 
observed, only due to the different policy characteristics in 
the most recently started trials. There is no evidence from 
the trials for a diminishing return with time for women aged 
50-69 years. 
EFFECTIVENESS IN PROGRAMMES 
Large European nationwide programmes, targeting all 
women in a certain age group at national level, have been 
initiated on the basis of the positive initial results from the 
trials. The United Kingdom launched its programme for 
women aged 50-64 years at 3-yearly intervals around 1987 
[lo], followed by The Netherlands in 1988 with a pro- 
gramme for women aged 50-69 at 2-yearly intervals [l l] 
and Finland for women aged 50-59 years initially at 2- 
yearly intervals. Apparently, the policy-makers agreed on 
only one thing, the lower age limit of 50. The United 
Kingdom predicted a 25% breast cancer mortality reduction 
rate for the invited group aged 50-64 years with the U.K. 
screening programme, emphasising the Kopparbergi 
Ostergotland results [ 121. In The Netherlands, predictions 
have been based on the reductions seen in the five Swedish 
randomised trials and the experience achieved in the pre- 
vious Nijmegen and Utrecht projects (regarding detection 
rates, interval cancers and stage distributions) [7, 91. A 17% 
reduction in the annual total female breast cancer mortality 
rate seems realistic, which is the same as approximately 
23% in the invited group (50-69 years). The age range in 
The Netherlands is, however, broader, and the screening 
interval shorter, which would make the U.K. estimates too 
optimistic according to the Dutch research [9, 131. 
Recently, researchers from the U.K. have also challenged 
the predictions [14]. Still, these possible reductions for 
women aged 50 years and over are tremendous substantial 
figures. In The Netherlands, each year 700-800 women will 
no longer die from breast cancer (metastases), in the U.K. 
this figure may possibly be 334 times more. The question 
is, therefore, no longer whether screening is effective, but 
how effective it is? 
Of course, the change in population breast cancer mor- 
tality, being the ultimate goal, cannot yet be seen, but both 
from the U.K. and the Dutch programme, nationwide 
results of the first years of the screening programmes are 
becoming available, on approximately 2.7 million and 1.0 
million screens, respectively [ 10, 111. In general, the first 
results are good. An attendance level between 70 and 80%, 
on average, is being reached, the number of women who 
need further assessment after screening is limited to 1.5-7(X 
and the detection rates at first screening are 6 to 7 per thou- 
sand screened women (in these populations with a relatively 
high background incidence). There is a substantial shift 
towards earlier detection reflected in favourable size distri- 
butions for tumours detected at screening, as well as in the 
more favourable axillary lymph node status. In the Dutch 
situation, these data are comparable or even better than in- 
itially anticipated; in the U.K. the anticipated size distri- 
bution for screen-detected cancers was suggested to be 
more favourable than the Dutch anticipation, and appears 
now to be generally the same as in the Dutch programme. 
Furthermore, the suggestion is that social-economic differ- 
ences do not influence the attendance rate in The 
Netherlands [ 151. 
The interval cancer rates are not yet known at the 
national level, but regional data from the U.K. suggest that 
these are higher than seen for instance in the Kopparbergi 
ijstergotland trial [ 14, 161. It is especially these data and 
the preliminary data on subsequent screens that might 
suggest a lower mortality reduction in the nationwide pro- 
grammes than seen in the Kopparberg/&tergGtland trial. 
Day and associates have estimated a 19% reduction in East 
Anglia, given the current rate of interval cancers [14]. 
Dutch investigators estimated a 21% reduction in the 
specific age group 50-64 if the U.K. policy had been chosen 
for The Netherlands [13] The message from the nation- 
wide programmes is, therefore, 2-fold: on the one hand, the 
initial process has been put in place with substantially im- 
portant achievements in the countries involved. While, on 
the other hand, much effort should still go into improving 
the nationwide results up to the highest standards possible. 
One must admit that the Kopparberg/&tergotland trial has 
shown the most favourable point estimate of all five 
Swedish trials [6, 93. In fact, all five Swedish randomised 
trials might be used as a reference in forecasting the 
expected reduction in other programmes, since these can be 
considered to give the most conclusive evidence on the 
effect of mammographic screening. However, detailed data 
on detection rates, interval cancers, stage distributions and 
the background situation are not (yet) available from each 
Swedish trial to give a correct interpretation of the impact 
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of any quality differences between the trials, and to make 
comparisons with the nationwide screening programmes. 
Meticulous monitoring of the nationwide programmes and 
comparisons with the predictions made will remain crucial. 
AGE CATEGORIES TO BE INVITED 
The discussion on the age categories of women to be 
invited for screening sometimes seems preoccupied with 
younger women. The upper age limit is as interesting but 
under-rated. Stating that breast cancer screening is clearly 
beneficial for women aged 50-69 years challenges one to 
make the statement that the same will apply at higher ages 
too. There is no ground to assume a substantial different 
natural course of disease nor a substantial different quality 
of mammography regarding the higher age groups. 
Scientifically, we are facing a problem, since randomised 
trials including older women is limited to the Kopparberg/ 
ijstergiitland trial, which included women up to 74 years of 
age at entry. Did women not live long enough at the start of 
the trials to include them? In the Swedish ‘overview’, the re- 
duction in women aged 70-74 years at entry was limited to 
6%, and confidence intervals were wide, but no major 
differences were found in ages 65-74 years at entry or 50- 
64 years at entry [ 171. Non-randomised results are available 
from Nijmegen and the U.S.A. only. The possible lower at- 
tendance rate has initially been put forward as a reason not 
to include women aged 65 years and over in the U.K. pro- 
gramme. The Dutch results now show no reason to support 
this with attendance levels only 5% less in women aged 65- 
69 years than for younger women. The U.K. Health Select 
Committee recently recommended that the upper age limit 
for inclusion in the call and recall system should be 
extended to 69 years [ 181. 
Boer and colleagues have shown that the number of 
breast cancer deaths prevented and life-years gained will 
increase substantially when extending the upper age limit of 
screening [ 191. The counterpart is an increase in lead time 
years, which are the extra number of years after the diagno- 
sis of breast cancer due to the earlier diagnosis by screening 
for some of the women. The higher probability of women 
dying from other causes (after screen-detection) and the 
possible larger increase in lead time years at older ages, 
makes screening programmes with upper age limits higher 
than 80 years of age unequally balanced towards unfavour- 
able effects of screening. A small loss in quality of life for 
the women involved, during such years in follow-up, can be 
assumed due to the experience of several medical follow-up 
procedures and by the negative impact on a woman’s qual- 
ity of life resulting from treatment and the knowledge that 
she has had breast cancer [20], although research has 
shown that with long follow-up, prevalence of anxiety and 
depression is not increased [21]. When starting a nation- 
wide programme, an upper age boundary of 75 years has to 
be carefully considered. For the already existing pro- 
grammes, emphasis should be put on establishing a high 
quality screening programme for the already invited age 
group, comparable to the earlier screening trials, before 
extending the programme to more women. 
Contrary to all the positive results for the older women, 
there was no hard evidence for a possible effect of breast 
cancer screening in women aged under 50 years of age. No 
single trial has shown a significant mortality reduction in 
this age group, and neither did the first ‘overview’ of the 
five Swedish trials combined including 800 000 person-years 
of follow-up [22]. It did show a lo-13% mortality re- 
duction, but only after 9 years of follow-up for women aged 
40-49 years at entry. Part of the observed mortality re- 
duction in these women is likely to have been a result of 
detecting the cancer earlier in later rounds when the women 
were 50 years or older [9]. With longer follow-up of the 
trials, this might lead to observed mortality reductions that 
are significant in this age group entering the trial, merely 
due to the beneficial effect of screening at older ages. True 
data on age at detection and mortality differences were not 
available until recently. Tabar and colleagues have shown 
that, in the women aged 40-49 years at randomisation, 
36% of the breast cancers were indeed diagnosed at age 50 
years and over. They could not find less benefit in the 
women with screen-detected cancers before age 50 than for 
cancers detected at later ages [23], but the other trials have 
not yet answered this question. The newest results from 
Sweden are again promising, showing a 23% reduction in 
the younger age group [24]. Before we value this as an 
equally effective programme in younger versus elderly 
women, it is crucial to have a reasonable estimate with 
regard to the amount of reduction achieved for these 
women entering the trials at younger ages on the basis of 
screening in later rounds (for all trials). 
Thus, it is possible that benefit may also be achieved in 
younger women under the age of 50 years. However, sensi- 
tivity of mammography is lower and the period that the 
cancer might be detected by screening before clinical diag- 
nosis is shorter. A shorter interval in the younger age group 
is thus needed, which brings us to cost-effectiveness. 
IS SCREENING COST-EFFECTIVE? 
Published cost-effectiveness ratios on breast cancer 
screening range remarkably. In a review of 16 such studies, 
the predicted cost per life-year saved ranged from USf 
3400 to 83 830 for screening women over the age of 49 
years [25]. This seems no real advertisement for cost-effec- 
tiveness analyses, in general, one would say. However, many 
factors influence the final ratio. The estimated cost of pro- 
viding the direct screening services is probably the most 
obvious one and is related to the price of screening and the 
frequency at which it is delivered to the population. If the 
16 studies are adjusted for this factor alone, the range 
becomes smaller, between US$ 9500 and 35 500. However, 
when examining two representative studies in detail, the 
Office of Technology Assessment-study [26] and the Dutch 
[7], the results reported are not as arbitrary as they seem. 
When comparably defined programmes are evaluated using 
similar assumptions about consequences, very similar results 
are obtained in the overview of approximately US$ 7000 
per life-year saved in both analyses. It is estimated that in 
the long-run, 47% of the annual cost of screening might be 
offset by savings due to a decrease in the number of women 
with advanced disease. If costs generated by screening are 
taken into account, one third of the cost of screening will be 
countered by savings in a 2-yearly programme for women 
aged 50-69 years. 
Thus, there is much evidence and well described research 
on the cost-effectiveness of breast cancer screening and for 
women aged 50 and over, high quality screening can be 
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considered to be cost-effective compared to other health- 
care programmes. The cervical cancer screening in The 
Netherlands, for instance, is three times more costly to gain 
one life-year. A 2- or 3-year interval breast programme is 
almost equally cost-effective, although the number (and %) 
of deaths prevented is substantially lower with a 3-year pro- 
gramme. Including women aged 40-49 years in a nation- 
wide programme was initially estimated to lead to a 
marginal cost-effectiveness ratio of approximately seven 
times higher cost for the same amount of life-years gained 
than for a nationwide programme inviting women aged 50 
years and over [7]. The newest results from Sweden will 
make the difference certainly smaller. 
ONE UNIFORM DECISION FOR ALL COUNTRIES 
WOULD BE INAPPROPRIATE 
The positive findings described above on the (cost-) 
effectiveness of screening women aged 50 years and over 
apply, in principal, to all countries with a similar population 
of women with breast cancer to that of the trials or those 
used in the cost-effectiveness analyses. It is, however, far 
from evident that each country should, therefore, start a 
nationwide programme. In countries with relatively low inci- 
dence and mortality rates of breast cancer, even in Europe, 
the cost-effectiveness ratio may be up to five times less 
favourable than for the U.K. or The Netherlands [27], 
simply because less absolute benefit is to be gained from 
screening if the burden of disease is less. A less frequent 
programme might be more appropriate comparing other 
health-care needs. Furthermore, there may be large differ- 
ences in cost in so-called decentralised systems, especially if 
related to the total health-care budget. In developing 
countries, the use of less costly screening services should be 
seriously considered. Even more important, estimates are 
based on potentially high quality programmes, considering 
the experience already present in parts of some countries. 
The critics may, of course, be right, in stating that high 
quality interpretation has to be taught and that high quality 
performance needs a well-established system with involve- 
ment of all disciplines and quality and evaluation assurance. 
Pilot projects in other countries should, therefore, be a 
guide in estimating more precisely the possible effects and 
cost of screening in other countries. German data showed a 
clear indication that improvement was needed in attendance 
and quality in order to achieve the same cost-effective ratios 
as seen in The Netherlands and the U.K. [28]. 
Therefore, while breast cancer screening is effective, this 
is dependent on the quality of the screening programme. 
Furthermore, the balance between favourable and unfavour- 
able effects for the woman is delicate. For 30% of women 
with screen-detected cancer, the screening programme will 
result in cure-they would otherwise have died of breast 
cancer. For each breast cancer death prevented, almost 
1000 screens will have to be done in countries with a high 
incidence. In particular, for those women with a positive 
test result needing further diagnostic assessment, quality of 
life is temporarily reduced. Furthermore, an increased inci- 
dence of 2% in breast cancer is expected from cancers 
detected in the programme that would not have been 













Finally, the most recent reduction in breast cancer mor- 
tality in England and Wales has led to some discussion: Is 
this due to the benefit of the nationwide screening pro- 
gramme, the benefit of (adjuvant systemic) treatment, or 
the earlier diagnosis of breast cancer outside the screening 
[30], or a cohort effect? The still relatively high incidence in 
the U.K. and especially the high mortality:incidence ratio 
makes a U.K. breast screening programme still highly cost- 
effective. It is difficult to interpret the intermingling with 
adjuvant systemic treatment for screen-detected cancers. 
Does the early detection mean detecting the cancer before 
important micrometastases have occurred (adjuvant treat- 
ment no additional benefit) or at a time when micrometas- 
tases can still be cured (additional benefit of treatment)? 
The trend towards earlier clinical diagnosis has also been 
used in postulating that the effect of the nationwide screen- 
ing programmes now being introduced is less than seen in 
the trials. If we assume that the general shortening of the 
delay between onset of disease and clinical diagnosis leads 
to a rather high and immediate 25% decrease in the chance 
of a breast cancer patient, not diagnosed via screening, 
dying of her disease, the cost-effectiveness ratio will be US$ 
6500 instead of US$ 4000; an important difference, but still 
a very favourable ratio to base your health policy upon. 
However, we are then forgeting the cost and effort needed 
and the unfavourable effects induced by achieving an earlier 
diagnosis outside of a regular screening programme. 
Unless the future tells us otherwise, high quality mass 
screening for breast cancer for women aged 50-75 years is 
relatively cost-effective. 
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FEMALE HEALTH AND BREAST CANCER 
RISKS AND TRENDS 
NEVER BEFORE in history have women in industrialised 
countries had a more favourable life expectancy than today; 
for those over 55 years of age, mortality for the major dis- 
eases is generally two to three times higher for males, so 
male life expectancy is 5 to 7 years shorter. Although breast 
cancer is the most frequent female cancer, 9 out of 10 
women ultimately will not develop breast cancer and 19 out 
of 20 will not die from it in North-Western Europe and the 
U.S.A. Whereas the incidence of breast cancer in most of 
these countries has increased at all ages according to birth 
cohort, and since the mid 197Os, upon the introduction of 
mammography, age-adjusted mortality rates have either 
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increased slightly or remained unchanged. They started to 
decline among premenopausal women (especially those 
born after 1950) in the high-incidence populations in the 
U.K., Switzerland, Holland, Scandinavia except Norway, 
and the U.S.A. [l]. For women over 70 years of age an 
increase was generally observed, while life expectancy rose 
by a few years. In Southern and Eastern Europe, the breast 
cancer rates are generally lower, but on the increase. In high 
incidence populations, relative lo-year survival for patients 
45-74 years of age with clinically detected cancer was more 
than 50%, being lower in populations with low incidence 
rates and/or a less favourable stage distribution [2]. Smaller 
and less aggressive cancers have increasingly been detected 
since the 197Os, even without organised screening pro- 
grammes [3], which probably lowers the gain of screening 
in the future. Moreover, wide application of effective hor- 
monal and cytotoxic therapy is likely to affect mortality 
from breast cancer [4]. 
